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Abstract
Mycoplasma hominis and Ureaplasma spp. may colonize the human genital tract and have been associated with adverse pregnancy outcomes
such as preterm labour and preterm premature rupture of membranes. However, as these bacteria can reside in the normal vaginal ﬂora, there
are controversies regarding their true role during pregnancy and so the need to treat these organisms. We therefore conducted a
retrospective analysis to evaluate the treatment of genital mycoplasma in 5377 pregnant patients showing symptoms of potential obstetric
complications at 25–37 weeks of gestation. Women presenting with symptoms were routinely screened by culture for the presence of these
bacteria and treated with clindamycin when positive. Compared with uninfected untreated patients, women treated for genital mycoplasma
demonstrated lower rates of premature labour. Indeed preterm birth rates were, respectively, 40.9% and 37.7% in women colonized with
Ureaplasma spp. and M. hominis, compared with 44.1% in uncolonized women (Ureaplasma spp., p 0.024; M. hominis, p 0.001). Moreover, a
reduction of neonatal complications rates was observed, with 10.9% of newborns developing respiratory diseases in case of Ureaplasma spp.
colonization and 5.9% in the presence of M. hominis, compared with 12.8% in the absence of those bacteria (Ureaplasma spp., p 0.050;
M. hominis, p <0.001). Microbiological screening of Ureaplasma spp. and/or M. hominis and pre-emptive antibiotic therapy of symptomatic
pregnant women in late pregnancy might represent a beneﬁcial strategy to reduce premature labour and neonatal complications.
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Introduction
Ureaplasma spp. and Mycoplasma hominis are members of the
Mycoplasmataceae family, characterized by their lack of a cell wall
and limited biosynthetic abilities. They are typically found in the
urogenital tract of men and women and are therefore often
referred to as ‘genital mycoplasma’ [1]. Ureaplasma spp. refer to
both Ureaplasma urealyticum (formerly U. urealyticum biovar 2)
and Ureaplasma parvum (formerly U. urealytica biovar 1), which
have recently been separated into two different species.
The potential pathogenic role of these bacteria during
pregnancy was recently reviewed [1]. Some studies have
shown an association of vaginal colonization by M. hominis or
Ureaplasma spp. with adverse pregnancy outcomes, such as
preterm labour [2,3], preterm premature rupture of mem-
branes (PPROM) [1] and chorioamnionitis [1]. Additionally,
maternal infection can lead to major neonatal complications
such as lung diseases, meningitis and septicaemia [4]. However,
other studies failed to demonstrate a pathogenic role of these
bacteria during pregnancy [1,5,6]. Hence, their exact role
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remains unclear and the beneﬁts of screening and treatment
strategies are still controversial.
In order to better address these issues, the present study
aims to evaluate the inﬂuence of vaginal colonization by
M. hominis and/or Ureaplasma spp. and of subsequent treat-
ment on pregnancy and neonatal outcomes.
Materials and Methods
Study design and population
This work is a retrospective study. Between 1998 and 2011,
we collected vaginal samples from pregnant women attending
the obstetrics department at University Hospital of Lausanne,
Switzerland. Vaginal samples were collected from women
between 25 and 37 weeks of gestation who exhibited obstetric
signs and symptoms such as uterine contractions, abdominal
pain, vaginal bleeding, suspicion of PPROM or cervical length
shortening on transvaginal ultrasound (<25 mm). These signs
and symptoms may be associated with adverse pregnancy
outcomes, notably premature labour, PPROM or chorioam-
nionitis and therefore justify speciﬁc investigations. All samples
were tested for the presence of M. hominis and Ureaplasma
spp. by culture. Patients whose samples were positive for one
or both bacteria were treated with clindamycin 150 mg four
times per day for 5 days. Demographic data, and adverse
pregnancy and neonatal outcomes among treated and
untreated women were subsequently analysed, using our
computerized obstetric database (DIAMM, http://www.
micro6.fr/) of prospectively collected data at the Maternity
Hospital of the University Hospital of Lausanne. The study was
approved by the ethics committee of the University and
Hospital, Lausanne, Switzerland (Protocol 46/14, date of
approval 12 February 2014).
Specimen collection and culture
Vaginal swabs were taken using the Copan e-swab kit
(Copan Diagnostics, Brescia, Italy). Specimens were placed on
culture medium plates speciﬁc for Ureaplasma spp. and M. ho-
minis (A7 Mycoplasma agar, BioMerieux, Marcy l’Etoile, France).
After 24–48 h of incubation in a low-concentration oxygen
atmosphere at 37°C, plates were analysed quantitatively by
inverse microscopy. Cultures positive for Ureaplasma spp. and/
or M. hominis were deﬁned morphologically as previously
described [1] and quantitative analysis was based on the
number of colonies per ﬁeld.
Statistical analysis
Categorical variables were compared using the Pearson
chi-square test. Differences in the means of normally distrib-
uted continuous variables were tested by the Student’s t-test
and differences in medians by the Mann–Whitney U-test.
Multivariable analyses were performed to control for covari-
ates. Multivariate logistic regressions were performed to
identify factors independently associated with prematurity
(birth <37 weeks of gestation). Multiple logistic regression
(stepwise) models were developed, and OR were used to
evaluate risk factors associated with prematurity. A two-tailed
p value <0.05 was considered signiﬁcant. Data were analysed
using STATA 13 (Stata Corporation, College Station, TX, USA).
Results
Of the 5377 patients tested, 2259 (42%) had a positive culture
for Ureaplasma spp. and/or M. hominis. Tables 1 and 2 show
the sociodemographic characteristics and associated outcomes
of women with a positive swab culture for Ureaplasma spp. and
M. hominis, respectively. Young age (p <0.001), nulliparity
(p 0.009), obesity (p 0.001), ethnicity (p <0.001) and cigarette
(p <0.001), alcohol (p 0.001) or drug (p <0.001) consumption
were identiﬁed as risk factors for Ureaplasma spp. and/or
M. hominis colonization during pregnancy in both univariate
and multivariate analyses.
Of the 5377 patients tested, 2296 (42.7%) delivered
prematurely (<37 weeks of gestation). Preterm birth occurred
less frequently in patients treated for genital mycoplasma
(Ureaplasma spp., p 0.024; M. hominis, p 0.001). Association
between treatment and reduced rate of preterm labour
remained signiﬁcant even when adjusted for other known risk
factors of premature labour, such as maternal age, cigarette
smoking, alcohol and drug consumption, obesity and ethnicity.
A multivariate logistic regression model associated with
M. hominis colonization is shown in Fig. 1. No difference was
observed in the rate of PPROM or mode of delivery. The
interval between swab collection and delivery was prolonged
by 6 days for Ureaplasma spp. (74 versus 68 days, p 0.027) and
11 days for M. hominis (79 versus 68 days, p 0.008) compared
with uninfected untreated patients. Duration of hospital stay
was reduced for treated women (Ureaplasma spp. p 0.021;
M. hominis p 0.017).
Early neonatal adaptation was similar between uninfected
women and women infected with Ureaplasma spp. and
M. hominis. However, neonates from treated women were
less frequently admitted to the neonatal intensive care unit
(NICU) (p <0.001) and had a shorter hospital stay (p <0.001).
Additionally, a signiﬁcant decrease in acute respiratory
complications was observed among neonates from treated
women (Ureaplasma spp., p 0.050; M. hominis, p <0.001)
compared with neonates from uninfected untreated women.
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Patients treated for a co-infection by both Ureaplasma spp.
and M. hominis exhibited similar reduction in preterm birth
(unadjusted OR 0.79, 95% CI 0.68–0.92; adjusted OR 0.84,
95% CI 0.72–0.98), neonatal stay >7 days (unadjusted OR 0.34,
95% CI 0.26–0.45; adjusted OR 0.36, 95% CI 0.27–0.47), NICU
admission (unadjusted OR 0.12, 95% CI 0.08–0.20; adjusted
OR 0.13, 95% CI 0.08–0.21) and respiratory diseases (unad-
justed OR 0.41, 95% CI 0.30–0.55; adjusted OR 0.42, 95% CI
0.31–0.57). Detailed data are shown in supplementary material
(Table S1).
Discussion
In this study, we focused on the effects of antimicrobial
treatment of vaginal mycoplasma colonization on symptomatic
pregnant women. We demonstrated a reduction of preterm
birth rate in patients treated for genital mycoplasma compared
with uninfected untreated women. Moreover, we showed a
striking reduction of neonatal complications in treated moth-
ers. Neonates born from treated mothers had fewer respira-
tory complications and were less frequently admitted to the
NICU compared with neonates from uninfected untreated
women.
The prevalence of colonization was signiﬁcant, with 42% of
screened women having a positive culture for either Ureapl-
asma spp. or M. hominis. Mycoplasma hominis was detected less
frequently than Ureaplasma spp., as previously reported [1,7,8].
Risk factors for colonization included young age, nulliparity,
obesity, non-Caucasian origin as well as consumption of
various drugs.
We recently reviewed the implications of Ureaplasma spp.
and M. hominis in adverse pregnancy outcomes [1]. Growing
evidence suggests a role of cervicovaginal colonization as well
as amniotic ﬂuid infection with both pathogens in adverse
pregnancy outcomes. Ureaplasma spp. and M. hominis are
sensitive to macrolides, clindamycin, quinolones and
tetracyclines. However, Ureaplasma spp. appear to be more
TABLE 1. Maternal and neonatal outcomes between patients with and without a positive vaginal swab culture to Ureaplasma
spp..
Negatives
(n = 3118)
Ureaplasma spp.
(n = 2221)
Unadjusted OR (95% CI)a Adjusted ORb (95% CI)No. % No. %
Maternal characteristics
Age (years), mean  SD 31.8  5.5 29.6  5.9
<25 370 11.9 516 23.2 1.00 1.00
25–35 1846 59.2 1298 58.4 0.51 (0.44–0.59) 0.54 (0.46–0.63)
>35 902 28.9 407 18.3 0.33 (0.28–0.39) 0.35 (0.29–0.42)
Nulliparous 1602 51.4 1220 54.9 1.15 (1.03–1.28) 1.02 (0.91–1.15)
BMI >30 kg/m2 641 20.6 548 24.7 1.28 (1.12–1.45) 1.32 (1.16–1.51)
Ethnicity
Caucasian 2304 73.9 1497 67.4 1.00 1.00
Black 238 7.6 270 12.2 1.21 (1.42–2.05) 1.68 (1.39–2.03)
Other 5761 18.5 454 20.4 1.21 (1.05–1.39) 1.29 (1.12–1.49)
Habits
Alcohol 11 0.3 24 1.1 2.86 (1.45–5.66) 2.42 (1.18–4.94)
Smoking 260 8.3 383 17.2 2.21 (1.87–2.61) 2.15 (1.80–2.56)
Drugs 21 0.7 44 2.0 2.64 (1.61–4.33) 1.52 (0.90–2.60)
Pregnancy outcomes
Gestational age (weeks, median) 37.3 38.0
Preterm birth (<37 weeks) 1376 44.1 908 40.9 0.88 (0.79–0.98) 0.95 (0.85–1.07)g
PPROM 587 18.8 414 18.6 0.99 (0.86–1.14) 1.08 (0.93–1.24)
Caesarean section 1343 43.1 904 40.7 0.91 (0.82–1.02) 1.03 (0.92–1.15)
Maternal stay >7 days 490 15.7 300 13.5 0.83 (0.71–0 .97) 0.93 (0.79–1.09)
Neonatal outcomes
Apgar <7 at 5 min 318 10.2 217 9.8 0.96 (0.80–1.15) 1.03 (0.85–1.24)
Arterial pH <7.1 84 3.0 56 2.8 0.92 (0.65–1.29) 0.97 (0.68–1.37)
Admission to NICU 425 13.6 235 10.6 0.75 (0.64–0.89) 0.80 (0.67–0.95)
Neonatal stay >7 days 527 16.9 290 13.1 0.74 (0.63–0.86) 0.80 (0.68–0.94)
Weight
SGAc 312 10.3 266 12.0 1.18 (0.99–1.40) 1.10 (0.93–1.32)
LGAd 414 13.3 275 12.4 0.93 (0.79–1.09) 0.97 (0.82–1.15)
Pathologies (any) 1365 43.8 918 41.3 0.91 (0.81–1.01) 0.96 (0.85–1.07)
Respiratory diseasese 398 12.8 243 10.9 0.84 (0.71–0 .99) 0.87 (0.73–1.03)
Infectious diseasesf 157 5.0 96 4.3 0.85 (0.66–1.10) 0.91 (0.70–1.19)
SD, standard deviation; BMI, body mass index; PPROM, preterm premature rupture of membranes; NICU, neonatal intensive care unit; SGA, small for gestational age; LGA, large
for gestational age.
aConﬁdence interval.
bAdjusted for maternal age, BMI >30 kg/m2, parity, ethnicity, smoking habits, as well as alcohol or drug consumption.
cBirthweight <10th centile.
dBirthweight >90th centile.
eIncludes apnoea, respiratory distress, hyaline membrane diseases and respiratory tract infections.
fIncludes septicaemia, infections limited to one organ; excludes respiratory tract infections.
gWhen adjusted only for parity, BMI, ethnicity and habits, preterm birth remains signiﬁcant (OR = 0.88, 95% CI 0.79–0.99).
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susceptible to macrolides whereas M. hominis responds better
to tetracyclines and quinolones. In the present study, clinda-
mycin was used in patients positive for genital mycoplasma. A
higher impact in terms of prevention of preterm birth and
adverse neonatal outcomes was identiﬁed for patients treated
for M. hominis compared with Ureaplasma spp., which can be
explained by the greater antibiotic susceptibility of M. hominis
[1].
The controversy regarding Ureaplasma spp. and M. hominis
treatment in pregnancy has hindered any deﬁnitive conclusions
regarding whether treatment for these mycoplasma affects
pregnancy outcomes and neonatal health [1]. One report
demonstrated the effectiveness of oral erythromycin in reducing
second-trimester spontaneous abortion in a case of genital
mycoplasma colonization. However, effects on premature
labour were inconclusive [9]. In a case of premature labour at
TABLE 2. Maternal and neonatal outcomes between patients with and without a positive vaginal swab culture to Mycoplasma
hominis
Negatives
(n = 3118)
M. hominis
(n = 912)
Unadjusted OR (95% CI)a Adjusted ORb (95% CI)No. % No. %
Maternal characteristics
Age (years), mean  SD 31.8  5.5 29.7  6.0
<25 370 11.9 216 23.7 1.00 1.00
25–35 1846 59.2 527 57.8 0.63 (0.52–0.75) 0.70 (0.58–0.85)
>35 902 28.9 169 18.5 0.46 (0.37–0.58) 0.53 (0.42–0.67)
Nulliparous 1602 51.4 529 58.0 1.28 (1.11–1.48) 1.21 (1.04–1.40)
BMI >30 kg/m2 641 20.6 222 24.3 1.16 (0.98–1.37) 1.17 (0.99–1.39)
Ethnicity
Caucasian 2304 73.9 610 66.9 1.00 1.00
Black 238 7.6 104 11.4 1.33 (1.05–1.68) 1.34 (1.06–1.70)
Other 576 18.5 198 21.7 1.24 (1.04–1.49) 1.31 (1.10–1.57)
Habits
Alcohol 11 0.3 8 0.9 1.40 0 (0.65–3.03) 1.23 (0.55–2.75)
Smoking 260 8.3 165 18.1 1.79 (1.48–2.17) 1.75 (1.43–2.14)
Drugs 21 0.7 21 2.3 2.21 (1.32–3.70) 1.51 (0.88–2.59)
Pregnancy outcomes
Gestational age (weeks, median) 37.3 38.1
Preterm birth (<37 weeks) 1376 44.1 344 37.7 0.78 (0.67–0.90) 0.82 (0.71–0.95)
PPROM 587 18.8 153 16.8 0.85 (0.71–1.03) 0.90 (0.74–1.09)
Caesarean section 1343 43.1 365 40.0 0.90 (0.78–1.05) 0.98 (0.85–1.14)
Maternal stay >7 days 490 15.7 112 12.3 0.77 (0.62–0.95) 0.82 (0.66–1.01)
Neonatal outcomes
Apgar <7 at 5 min 318 10.2 84 9.2 0.90 (0.71–1.15) 0.94 (0.73–1.20)
Arterial pH <7.1 84 3.0 25 3.0 1.04 (0.67–1.60) 1.07 (0.69–1.66)
Admission to NICU 425 13.6 22 2.4 0.15 (0.10–0.23) 0.15 (0.10–0.24)
Neonatal stay >7 days 527 16.9 63 6.9 0.36 (0.28–0.47) 0.39 (0.29–0.50)
Weight
SGAc 312 10.3 102 11.2 1.02 (0.82–1.28) 0.95 (0.76–1.20)
LGAd 414 13.3 108 11.9 0.89 (0.72–1.11) 0.94 (0.75–1.17)
Pathologies (any) 1365 43.8 384 42.1 0.97 (0.84–1.12) 1.00 (0.87–1.17)
Respiratory diseasese 398 12.8 54 5.9 0.41 (0.31–0.55) 0.42 (0.32–0.57)
Infectious diseasesf 157 5.0 8 0.9 0.15 (0.08–0.30) 0.16 (0.08–0.33)
SD, standard deviation; BMI, body mass index; PPROM, preterm premature rupture of membranes; NICU, neonatal intensive care unit; SGA, small for gestational age; LGA, large
for gestational age.
aConﬁdence interval.
bAdjusted for maternal age, BMI >30 kg/m2, parity, ethnicity, smoking habits, as well as alcohol or drug consumption.
cBirthweight <10th centile.
dBirthweight >90th centile.
eIncludes apnoea, respiratory distress, hyaline membrane diseases and respiratory tract infections.
fIncludes septicaemia, infections limited to one organ; excludes respiratory tract infections.
FIG. 1. Multivariate logistic regression
model to identify risk factors of
premature birth. This ﬁgure represents
the adjusted OR, with corresponding 95%
CI, in a logarithmic scale.
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27 weeks of gestation, which was associated with U. urealyticum
colonization, Smorgick et al. observed that treatment with
erythromycin, ﬂuoroquinolones and clindamycin prolonged the
pregnancy until 33 weeks, when spontaneous labour occurred.
Cultures from the placenta were sterile but histopathological
signs of chorioamnionitis were documented in placental samples
[10]. Similarly, Romero et al. [11] observed that treatment with
erythromycin, clindamycin, ampicillin and gentamicin prolonged
the pregnancy for 22 days, although spontaneous labour still
occurred prematurely in a case where PPROM was associated
with Ureaplasma spp. colonization. Such observations were
conﬁrmed in a non-human primate model. Indeed, in U. par-
vum-induced chorioamnionitis, intravenous azithromycin pro-
longed the pregnancy and prevented advanced fetal lung injury,
despite the persistence of residual acute chorioamnionitis [12].
Hence, a different hypothesis may explain why antimicrobial
treatment of intra-amniotic infection with mycoplasma may be
beneﬁcial to the fetus. First, intra-amniotic infection may
trigger accelerated fetal lung maturation leading to a lower risk
of respiratory distress after birth [13]. Moreover, antibiotic
treatment of infected mothers may further improve neonatal
outcomes by: (i) limiting intra-amniotic bacterial load and
therefore reducing subsequent fetal inﬂammatory response
and induced lung injury [12] and (ii) prolonging pregnancy, so
reducing the risk of respiratory problems due to lung
immaturity.
Limitations of our retrospective study include the lack of
information on patient compliance. Another limitation of our
study is the lack of information regarding previous preterm
labour. Additionally, U. urealyticum and U. parvum were not
identiﬁed at the species level. Moreover, our study was made
on a symptomatic population and thus at higher risk of adverse
pregnancy outcomes compared with asymptomatic women.
This is conﬁrmed by the high prevalence of premature labour
in our study (42.7%) compared with the general population, in
which it only affects c.10% of pregnancies [14].
In addition, we did not investigate the effects of Ureaplasma
spp. and M. hominis on pregnancy and neonatal outcomes, but
instead analysed the impacts of their treatment. Therefore, our
results might also be explained by the eradication of other
pathogenic agents susceptible to clindamycin that were not
detected in our study. For example, Waddlia chondrophila and
Parachlamydia acanthamoebae, not detected on routine culture
media, have been shown to be implicated in human adverse
pregnancy outcomes [15–17] and are both sensitive to clinda-
mycin and macrolides [18,19]. A similar conclusion can be made
for Chlamydia trachomatis [16,17,20] or the presence of bacterial
vaginosis [21], which we did not evaluate. Our results might
therefore be explained by the use of clindamycin in late
pregnancy and not by the eradication of Ureaplasma spp. or
M. hominis, especially as we have no information on the
clearance of the urogenital mycoplasma. Two recent
meta-analyses on the efﬁcacy of clindamycin in preventing
preterm labour in cases of bacterial vaginosis concluded with a
reduction in the preterm birth rate when treatment was
achieved in the second trimester [22,23]. Additionally, a recent
review in the Cochrane Library [24] concluded with a prolon-
gation of pregnancy and the reduction of a number of short-term
neonatal complications when antibiotics where giving in cases of
PPROM. Clindamycin might be effective in reducing preterm
labour either by eradicating pathogens or simply by reducing
inﬂammation. However, in a recent report, Diaz-Cueto et al.
showed that clindamycin was effective in reducing two impor-
tant inﬂammationmediators, interleukin-1 and interleukin-6, but
not the metalloproteinase 8 [25]. This could lead to cervical
extracellular matrix degradation and subsequent induction of
premature labour. Hence, the authors concluded that there was
inefﬁcacy in reducing preterm birth associated with bacterial
vaginosis. Despite such contradictory data, which led to
controversies in the ﬁeld, the present work on more than
5000 patients strongly supports the use of clindamycin when
urogenital mycoplasma are detected in such situations.
In conclusion, we demonstrate the beneﬁts of treating genital
mycoplasma during pregnancy because it is associated with a
lower rate of preterm birth and better neonatal outcomes.
Therefore, we recommend screening of symptomatic pregnant
women for whom an adverse pregnancy outcome is suspected
for the presence of these bacteria and administration of prompt
treatment when positive. Further investigations are needed to
know whether routine treatment of all symptomatic patients
with clindamycin might decrease the rate of adverse pregnancy
outcomes even when neither colonized nor infected by genital
mycoplasma by eradicating emerging pathogenic intracellular
bacteria such as Chlamydia-related bacteria or other commonly
adverse pregnancy-associated pathogens such as C. trachomatis
or bacterial vaginosis.
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